Loading…
Compugen Ltd. is projected to rise to $3.08 by 2027, a +12% move from its current price of $2.76. CGEN is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $2.66 | $2.76 | $2.86 | -0.01% |
| May 30 | $2.62 | $2.76 | $2.91 | -0.01% |
| May 31 | $2.59 | $2.76 | $2.94 | -0.02% |
| Jun 1 | $2.56 | $2.76 | $2.97 | -0.03% |
| Jun 2 | $2.54 | $2.76 | $2.99 | -0.04% |
| Jun 3 | $2.52 | $2.76 | $3.02 | -0.04% |
| Jun 4 | $2.50 | $2.76 | $3.04 | -0.05% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.50 | $2.76 | $3.04 | -0.05% |
| Week 2 | $2.40 | $2.76 | $3.16 | -0.10% |
| Week 3 | $2.33 | $2.76 | $3.26 | -0.15% |
| Week 4 | $2.27 | $2.75 | $3.34 | -0.20% |
| Week 5 | $2.22 | $2.75 | $3.42 | -0.25% |
| Week 6 | $2.17 | $2.75 | $3.49 | -0.30% |
| Week 7 | $2.13 | $2.75 | $3.55 | -0.35% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Compugen Ltd. is a clinical-stage therapeutic discovery and development company focused on immuno-oncology. Its pipeline includes COM701, an immuno-oncology program with an anti-PVRIG antibody, and COM902, a therapeutic anti-TIGIT antibody, both in Phase 1 clinical trials and evaluated for solid tumors as a monotherapy and in combination with PVRIG/PD-1 or PVRIG/TIGIT blockade.
The portfolio also includes Bapotulimab, a therapeutic antibody targeting ILDR2 in Phase I, and Rilvegostomig, a novel anti-PD-1/TIGIT bispecific antibody in Phase III for advanced or metastatic non-small cell lung cancer, along with preclinical programs and COM503, which blocks the interaction between IL-18 binding protein and IL-18. The company maintains collaboration with Bristol-Myers Squibb to evaluate COM701 with Opdivo and has license agreements with AstraZeneca and Gilead Sciences for related immuno-oncology programs. It was incorporated in 1993 and is headquartered in Holon, Israel.
Compugen Ltd. (CGEN) trades as a healthcare stock with a current price of $2.80 and a market capitalization of $264.84M. Its rank is 3629 in market position. The long-run price outlook shows meaningful upside across the forecast horizon, with averages rising from $2.80 in 2026 to $34.66 in 2050 and annualized returns that climb across the period.
A major floor 42.4% below — a decisive break under it would weaken the trend.
The nearest floor, 5.8% below — buyers have tended to step in here.
The nearest ceiling, 12.3% above — a clean break opens room to run.
A major ceiling 20.3% above — clearing it would confirm fresh momentum.
Key CGEN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CGEN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.71 | Buy | $2.73 | Buy |
| MA 10 | $2.77 | Sell | $2.75 | Buy |
| MA 20 | $2.76 | Sell | $2.75 | Buy |
| MA 50 | $2.58 | Buy | $2.59 | Buy |
| MA 100 | $2.24 | Buy | $2.34 | Buy |
| MA 200 | $1.91 | Buy | $2.08 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 51.32 | Neutral |
| Stoch RSI (14) | 30.22 | Neutral |
| CCI (20) | -3.79 | Neutral |
| Williams %R (14) | -64.29 | Info |
| MACD (12,26,9) | -0.03 | Sell |
| ROC (12) | -4.83 | Sell |
| Bollinger %B (20,2) | 0.49 | Neutral |
| Stochastic %K (14) | 35.71 | Neutral |
| TRIX (15) | 0.31 | Buy |
| Awesome (5,34) | -0.08 | Sell |
| Ultimate (7,14,28) | 50.02 | Neutral |
| Momentum (10) | -0.07 | Sell |
| Aroon Osc (25) | -12.00 | Sell |
| Hull MA (9) | 2.68 | Buy |
| ADX (14) | 14.78 | Neutral |
| ATR (14) | 0.10 | Info |
The 30-day technical picture remains constructive with sentiment labeled as BULLISH and RSI(14) at 50. The stock trades above the SMA50 of $2.56 and above the SMA200 of $1.90, suggesting a positive near-term drift. The key support is seen at $2.60 and resistance at $3.10, reflecting a measured range within a 30-day window from $2.21 to $3.55.
Annualized volatility stands at 70%, underscoring notable swing potential in the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.52 | $2.76 | $3.65 | 0% | Neutral | |
| $2.36 | $3.08 | $4.30 | +12% | Neutral | |
| $2.77 | $3.75 | $5.48 | +36% | Bullish | |
| $3.55 | $4.97 | $7.52 | +80% | Bullish | |
| $3.94 | $5.68 | $8.86 | +106% | Bullish | |
| $3.86 | $5.70 | $9.13 | +107% | Bullish | |
| $3.99 | $6.04 | $9.91 | +119% | Bullish | |
| $4.01 | $6.22 | $10.42 | +126% | Bullish | |
| $4.48 | $7.10 | $12.13 | +157% | Bullish | |
| $5.62 | $9.10 | $15.83 | +230% | Bullish | |
| $6.51 | $11.67 | $21.86 | +323% | Bullish | |
| $12.45 | $26.78 | $55.86 | +870% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $1.52 | $2.76 | $3.23 | +0.00% |
| June 2026 | $2.24 | $2.65 | $3.23 | -3.82% |
| July 2026 | $2.29 | $2.74 | $3.40 | +3.28% |
| August 2026 | $2.31 | $2.79 | $3.50 | +1.77% |
| September 2026 | $2.23 | $2.71 | $3.44 | -2.91% |
| October 2026 | $2.24 | $2.74 | $3.51 | +1.05% |
| November 2026 | $2.32 | $2.86 | $3.69 | +4.29% |
| December 2026 | $2.26 | $2.80 | $3.65 | -1.91% |
Click any year to see its month-by-month CGEN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The CGEN price prediction for 2026 points to an average of $2.76 (low $1.52, high $3.65) — a potential gain of 0% on today's $2.76. Price action looks broadly range-bound.
In 2027, CGEN is projected to trade between $2.36 and $4.30, averaging $3.08 — a potential gain of +12% from today's $2.76. That is up +12% on the projected 2026 average. A consolidation phase looks the most probable path here.
Compugen Ltd.'s 2028 outlook centres on $3.75, within a $2.77 to $5.48 range. That is up +22% on the projected 2027 average. That marks a +36% change versus current levels. Momentum favours further upside here.
By 2029, CGEN could reach as high as $7.52, with a base case around $4.97 and support toward $3.55 — roughly +80% from $2.76. Buyers look set to stay in control over this stretch.
Expect CGEN to range from $3.94 to $8.86 through 2030. The $5.68 average target implies a +106% move from current prices. That is up +14% on the projected 2029 average. Momentum favours further upside here.
The CGEN price prediction for 2031 points to an average of $5.70 (low $3.86, high $9.13) — a potential gain of +107% on today's $2.76. Buyers look set to stay in control over this stretch.
In 2032, CGEN is projected to trade between $3.99 and $9.91, averaging $6.04 — a potential gain of +119% from today's $2.76. That is up +6% on the projected 2031 average. Momentum favours further upside here.
Compugen Ltd.'s 2033 outlook centres on $6.22, within a $4.01 to $10.42 range. That is up +3% on the projected 2032 average. That marks a +126% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, CGEN could reach as high as $12.13, with a base case around $7.10 and support toward $4.48 — roughly +157% from $2.76. Momentum favours further upside here.
Expect CGEN to range from $5.62 to $15.83 through 2035. The $9.10 average target implies a +230% move from current prices. That is up +28% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The CGEN price prediction for 2040 points to an average of $11.67 (low $6.51, high $21.86) — a potential gain of +323% on today's $2.76. Momentum favours further upside here.
In 2050, CGEN is projected to trade between $12.45 and $55.86, averaging $26.78 — a potential gain of +870% from today's $2.76. That is up +130% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in CGEN today (≈ 362.318841 CGEN) could be worth
$9,702.15
+$8,702.15 (+870%) by 2050 · US Dollar
Based on the average projected CGEN price of $26.78 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CGENwould be worth at today's price.
$1,000 invested in CGEN on May 27, 2025 (≈ 699.300725 CGEN) would be worth
$1,930.07
+$930.07 (+93.0%) today · 1.93× · US Dollar
Based on a CGEN entry price of $1.43 vs. today's $2.76.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.71 | $1,018.45 | +1.8% |
| 1 month ago | $2.92 | $945.21 | -5.5% |
| 3 months ago | $1.79 | $1,541.9 | +54.2% |
| 6 months ago | $1.56 | $1,769.23 | +76.9% |
| 1 year ago | $1.43 | $1,930.07 | +93.0% |
| All time (5.0y) ago | $7.69 | $358.91 | -64.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CGEN forecast.
Our base-case forecast reaches $5.50 around 2030.
Implied market cap at $5.50: $520.22M
The multi-year forecast shows a clear upward trajectory with progressively higher averages and substantial upside potential. The 2026 average is $2.80 with a 0% ROI and neutral sentiment, signaling a starting base. By 2027 the average is $3.30 (ROI 18) and neutral sentiment, expanding to 2028 average $4.21 (ROI 50.3) with bullish sentiment.
In 2029 the average reaches $5.53 (ROI 97.7), and by 2030 the average is $6.42 (ROI 129.5), with bullish sentiment continuing. The forecast extends through 2031 ($6.55, ROI 133.9), 2032 ($6.98, ROI 149.3), 2033 ($7.44, ROI 165.8), and 2034 ($8.69, ROI 210.3), all noted as bullish. By 2035 the average is $11.13 (ROI 297.6) and bullish, and the momentum remains strong into 2040 ($14.93 average, ROI 433.2) with bullish sentiment.
The final year here, 2050, shows an average of $34.66 (ROI 1138) and bullish sentiment, with a max of $71.91 and a min of $16.29. These are estimates, not guarantees, and depend on clinical, regulatory, and market conditions.
Tap a question to reveal the answer.
The forecast shows a 2030 average of $6.42 with a min of $4.48 and a max of $10.00, and a ROI of 129.5%. The sentiment is BULLISH.
The long-term projections indicate a bullish path with 2040 average $14.93 and 2050 average $34.66, yielding ROI of 433.2% and 1138%, respectively. Short-term 2026 average is $2.80 with neutral sentiment, and 2027 is $3.30 (ROI 18) with neutral sentiment.
According to the forecast, the 2035 max is $19.27 and the 2040 max is $27.84, so surpassing $20 is possible by 2040, but not by 2035.
Current price is $2.80 and market capitalization is $264.84M.
The 30-day range spans from a low of $2.21 to a high of $3.55, with support at $2.60 and resistance at $3.10.
Compugen Ltd. Community Discussion
0Share your Compugen Ltd. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.